---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-397870"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2026-09-22T20:01:33+00:00"
generated_at: "2026-09-22T20:02:13.813089+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion moves BMF-650 Phase I topline readout to October 2026

## Summary
- Company now expects topline results for BMF-650 Phase I (GLP-131) in October 2026.
- Trial enrolls obese, otherwise healthy volunteers; no results disclosed yet.
- Timing update issued September 22, 2026; prior expectation unspecified.

## SEC filing metadata
- accession: 0001193125-26-397870
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2026-09-22T20:01:33+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312526397870/0001193125-26-397870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312526397870/bmea-20260922.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-397870
- JSON: https://secwatch.observer/filing/0001193125-26-397870.json
- Plain text: https://secwatch.observer/filing/0001193125-26-397870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.